bh009
Bioequivalence
Zhuhai Beihai Biotech Co., LtdPhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Bioequivalence cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Docetaxel Zhuhai Beihai Biotech Co., Ltd | Phase 3 | B |
Pomalidomide Jiangsu Simcere Pharmaceutical Co., Ltd. | Phase 1 | CC |
AMISULPRIDE The Affiliated Hospital of Qingdao University | Phase 1 | CC |
Inno-206 CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | N/A | D |
Same molecule, other indications
bh009 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →